During the third quarter, GDS Wealth Management trimmed its UnitedHealth Group position by 10.7%, offloading 5,297 shares and finishing with a 44,252-share holding valued at approximately $15.28 million. Cullen Frost Bankers followed suit in the same period, reducing its stake by 27.1% through the sale of 29,527 shares, leaving it with 79,459 shares valued at roughly $27.44 million. Across the broader institutional landscape, smaller advisory firms including LFA Lugano Financial Advisors, Sagard Holdings Management, Grey Fox Wealth Advisors and Islay Capital Management initiated new positions ranging from $25,000 to $33,000, while Riggs Asset Management boosted its holding by 69.4% to 105 shares worth $33,000. Hedge funds and other institutions now control 87.86% of UnitedHealth’s shares, underscoring the stock’s concentration among large investors.

UnitedHealth’s latest quarterly report delivered earnings per share of $2.92, surpassing consensus estimates by $0.05, on revenue of $113.16 billion, essentially in line with the $113.19 billion forecast. Revenue rose 12.2% year-over-year, driven by growth across both UnitedHealthcare and Optum segments. The company reported a net margin of 4.04% and a return on equity of 19.23%. Key balance-sheet ratios remained stable, with a debt-to-equity ratio of 0.71 and a current ratio of 0.82. Analysts project full-year EPS of 29.54, supported by strong free cash flow generation and a diversified revenue base spanning commercial employer plans, Medicare and Medicaid programs.

In recent weeks, Jefferies upgraded its price target from $317 to $409 and maintained a Buy recommendation, while Goldman Sachs initiated coverage with a Buy rating and a $406 target. UBS raised its target from $378 to $430, Piper Sandler set an Overweight rating with a $417 objective and Mizuho lifted its target from $300 to $430 alongside an Outperform rating. Among 29 analysts, one rates the stock as Strong Buy, 17 as Buy, nine as Hold and two as Sell, resulting in a consensus ‘Moderate Buy’ with an average target of $386.33. UnitedHealth paid a fourth-quarter dividend of $2.21 per share, equating to an $8.84 annualized payout and a 2.5% yield, with a payout ratio of 46.14%, well supported by normalized free cash flow.